BCA
MCRB icon

Berman Capital Advisors’s Seres Therapeutics MCRB Stock Holding History

Berman Capital Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Hold
12
– – ﹤0.01% 1906
2021
Q2 		$5K Hold
12
– – ﹤0.01% 1354
2021
Q1 		$5K Hold
12
– – ﹤0.01% 1275
2020
Q4 		$5K Hold
12
– – ﹤0.01% 1155
2020
Q3 		$6K Sell
12
-7
-37% -$2.33K ﹤0.01% 970
2020
Q2 		$1K Buy
+19
New +$1.67K ﹤0.01% 1448

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's MCRB Position: Q3 2021 in Review

Berman Capital Advisors held its Seres Therapeutics (MCRB) position steady in Q3 2021 at 12 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Berman Capital Advisors first reported a position in MCRB in Q2 2020 and has held it in 6 quarters since. The position peaked at $6K in Q3 2020. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Berman Capital Advisors held 12 shares of Seres Therapeutics worth $1K as of Q3 2021.
  • Berman Capital Advisors left its Seres Therapeutics share count unchanged in Q3 2021.
  • Seres Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1906 holding.
  • Berman Capital Advisors first reported a position in Seres Therapeutics in Q2 2020 and has held it in 6 quarters since.
  • Berman Capital Advisors's Seres Therapeutics position peaked at $6K in Q3 2020.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.